Core Viewpoint - Mereo BioPharma Group plc reported financial results for the year ended December 31, 2025, highlighting ongoing studies of setrusumab for osteogenesis imperfecta and a financial runway into mid-2027 with $41.0 million in cash [1][10]. Financial Performance - Total research and development expenses decreased by $3.2 million from $20.9 million in 2024 to $17.8 million in 2025, primarily due to reductions in expenses for alvelestat and etigilimab [7]. - General and administrative expenses decreased by $3.4 million from $26.4 million in 2024 to $23.0 million in 2025, attributed to lower accruals for bonuses and reduced professional fees [8]. - The net loss for the full year ended December 31, 2025, was $41.9 million, compared to $43.3 million in 2024, reflecting an operating loss of $40.1 million and a foreign currency translation loss of $6.3 million [9]. - As of December 31, 2025, the company had cash and cash equivalents of $41.0 million, down from $69.8 million in 2024, expected to fund operations into mid-2027 [10]. Product Development and Regulatory Updates - Setrusumab has shown statistically significant improvements in bone mineral density and reductions in vertebral fractures, although it did not achieve statistical significance against primary endpoints in the Phase 3 studies [5]. - The company is in discussions with regulatory agencies regarding the ongoing analyses of data from the Phase 3 Orbit and Cosmic studies of setrusumab [2]. - Mereo anticipates a single Phase 3 trial for alvelestat, enrolling approximately 220 patients, to support regulatory submissions in the U.S. and Europe [5]. - The company has retained EU and UK commercial rights for setrusumab and is in active discussions for the Phase 3 development and commercialization of alvelestat [14]. Shareholder Information - Total ordinary shares issued as of December 31, 2025, were 795,658,504, with total ADS equivalents of 159,131,700 [11]. - The accumulated deficit as of December 31, 2025, was $501.0 million, compared to $462.9 million in 2024 [19].

Core Viewpoint - Mereo BioPharma is updating its cash runway guidance and providing insights into its ongoing clinical programs, particularly focusing on setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency-associated lung disease [1][2][3]. Group 1: Setrusumab Program - The Phase 3 Orbit and Cosmic studies of setrusumab did not achieve statistical significance for the primary endpoints related to fracture reduction compared to placebo or bisphosphonates, but showed significant improvement in bone mineral density as a key secondary endpoint [4]. - The safety profile of setrusumab remains consistent with previous studies, and further analyses are ongoing to determine the next steps, including potential regulatory interactions [5][4]. - There is a high unmet medical need for treatments in osteogenesis imperfecta, with no FDA or EMA approved therapies available, highlighting the importance of setrusumab in addressing this condition [6][7]. Group 2: Alvelestat Program - Mereo is advancing preparations for a global Phase 3 pivotal study of alvelestat, which is expected to enroll approximately 220 patients over an 18-month treatment period [8]. - The primary efficacy endpoint for U.S. approval will be the St. George's Respiratory Questionnaire Total Score, while lung density measured by CT scan will serve as the primary endpoint for potential European regulatory approval [9]. - The company is actively engaging in discussions with potential partners for the development and commercialization of alvelestat [9]. Group 3: Financial Position - As of December 31, 2025, Mereo reported a cash balance of approximately $41 million, which is expected to fund operations until mid-2027 [1][2].